A Single Dose Study to Investigate the Pharmacokinetics of Ridaforolimus in Patients With Hepatic Insufficiency
Interventional
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
AUC(0-infinity) of ridaforolimus following a single oral dose
through 288 hours post dose
No
Medical Monitor
Study Director
Merck
United States: Food and Drug Administration
2009_706
NCT01043887
January 2010
April 2010
Name | Location |
---|